Loading…
Employees: 751
Size Shanghai Lily & Beauty Cosmetics (605136.SS) is a China Health Care company (Medical Distributors) with a market value of $517M, the 3789th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.65 on 6 Nov 2026.
Performance Over six months the shares fell 20.9%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 10.1% over the last twelve months (peer median +2.1%); the operating margin is -0.2% (peer median 1.6%).
Valuation It trades at 1.2× enterprise value to sales against a peer median of 1.3× (10th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is -18%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.7 points below its cost of capital (7.5% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.75B | CN¥1.68B | CN¥1.71B | CN¥2.75B | CN¥3.23B |
| Revenue growth | — | -2% | -38% | -15% | — |
| Gross profit | CN¥696M | CN¥649M | CN¥585M | CN¥923M | CN¥846M |
| EBITDA | CN¥11.9M | -CN¥73.0M | -CN¥38.3M | CN¥34.1M | -CN¥198M |
| Net income | -CN¥24.7M | -CN¥80.0M | -CN¥24.4M | CN¥29.5M | -CN¥139M |
| Free cash flow | CN¥72.9M | CN¥123M | CN¥444M | CN¥219M | CN¥128M |
| Capital expenditure | CN¥18.1M | CN¥11.4M | CN¥4.04M | CN¥4.05M | CN¥5.51M |
| Total debt | CN¥30.5M | CN¥74.5M | CN¥89.6M | CN¥264M | CN¥415M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605136.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.8% | -1.8% | 9th highest of 21 |
| 6-month return | -20.9% | -5.6% | 6th lowest of 21 |
| Distance from 52-week high | -39.0% | -20.4% | 6th lowest of 21 |
| Revenue growth (TTM) | +10.1% | +2.1% | 6th highest of 21 |
| Operating margin | -0.2% | 1.6% | 8th lowest of 21 |
| EV / Sales | 1.2× | 1.3× | 10th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 12.2% | 1.6% | 5th most demanding of 15 |
| Growth delivered (Del g) | -18.1% | +5.8% | lowest of 15 |
| Hurdle (Req g minus delivered) | +30.3 pp | -4.1 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | -7.7 pp | -2.0 pp | 6th lowest of 20 |
| Net debt / EBITDA | -112.7× | 1.3× | least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | 0.6× | 59.0% | -7.8% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | 0.1× | 0.4% | +2.6% |
| Excelsior Medical 4104.TW | Taiwan | $409M | +1% | +6% | 8% | 1.6× | 2.9% | +5.7% |
| Gongwin Biopharm 6617.TWO | Taiwan | $388M | +50% | +22% | -571% | 267.5× | n/a | n/a |
| Shanghai Universal Biotech 301166.SZ | China | $376M | -6% | +15% | -4% | 1.2× | n/a | n/a |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Rongfeng 000668.SZ | China | $327M | -5% | +61% | 14% | 5.3× | 11.4% | +30.0% |
| Medios ILM1.DE | Germany | $324M | -9% | +10% | 2% | 0.2× | -1.3% | +27.1% |
| Goodwill E-Health Info 688246.SS | China | $323M | -25% | -30% | -68% | 6.4× | n/a | n/a |
| Nagaileben 7447.T | Japan | $319M | -1% | +1% | 22% | 1.6× | n/a | n/a |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Shanghai Pioneer 1345.HK | Hong Kong | $300M | -18% | -6% | 11% | 1.7× | -6.7% | -1.4% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $926M | -27% | -5% | -2% | 2.0× | 17.2% | +12.4% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |